All In Biotech

Drug Trial Radar · NCT05945888

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 3000202 Administered as Tablet to Healthy Male Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Relative Bioavailability Comparison of BI 3000202 as Tablet With and Without Food in Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

68

Actual

Start

Jul 25, 2023

Primary completion

Nov 13, 2023

Study completion Nov 13, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The single rising dose (SRD) part of the trial investigates safety, tolerability, and pharmacokinetics of BI 3000202. The food effect (FE) part is conducted to assess the effect of food on the relative bioavailability of the BI 3000202 formulation.

Conditions

  • Healthy

Interventions

  • BI 3000202Drug

    BI 3000202

  • Placebo matching BI 3000202Drug

    Placebo matching BI 3000202

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SRD Part: Number of Any Treatment-emergent Adverse Event Assessed as Drug-related by the InvestigatorTime frame: From drug administration on Day 1 plus REP of 48 hours, up to 2 days.
  2. FE Part: Area Under the Concentration-time Curve of BI 3000202 in Plasma Over the Dosing Interval 0 to 24 Hours (AUC0-24)Time frame: Within 3 hours (h) prior to and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, and 48 h after drug administration
  3. FE Part: Maximum Measured Concentration of BI 3000202 in Plasma (Cmax)Time frame: Within 3 hours (h) prior to and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, and 48 h after drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Humanpharmakologisches Zentrum Biberach

    Biberach, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.